Edition:
United Kingdom

Profile: Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

5.49CAD
21 Aug 2019
Change (% chg)

-- (--)
Prev Close
$5.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
106,920
52-wk High
$11.45
52-wk Low
$4.86

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.

Company Address

Theratechnologies Inc

2015 Peel St 5th Floor
MONTREAL   QC   H3A 1T8
P: +1514.3367800
F: +1514.3367800

Company Web Links